Navigation Links
Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids

mmented Joseph Podolski, President and CEO of Repros. "This analysis confirms our interim assessment. Proellex has demonstrated profound effects in relieving symptoms and in improving quality of life in a common and debilitating female disease for which there have been limited drug choices. We believe that Proellex has the potential to provide a major improvement in treating uterine fibroids."

About Repros Therapeutics Inc.

Repros is engaged in the development of pharmaceutical products that address conditions of the male and female reproductive systems. Proellex(TM), the Company's lead compound, is a selective blocker of the progesterone receptor. Having successfully completed the above Phase 2 trial the Company believes Proellex will enter Phase 3 studies later this year for the treatment of symptoms associated with uterine fibroids, a condition that affects numerous women of childbearing age in the U.S. and results in a significant number of hysterectomies each year. In addition Proellex(TM) is being studied in a European Phase 1/2 clinical trial of symptoms associated with endometriosis, a condition that affects approximately 5.5 million women in the U.S. and Canada. Androxal(TM), the Company's other program in late clinical development, is designed to restore normal testosterone production by the testes and is being tested in a non-pivotal U.S. Phase 3 clinical trial for the treatment of testosterone deficiency in men due to secondary hypogonadism.

For more information, please visit the Company's website at http://www.reprosrx.com.

Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Repros' ability to have success in the clinical development of its technologies, the timing of enrollment in such clinical studies and the accuracy of such studies, limited patient populations of clinical studies to date and the possibility that final data ma
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
2. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
3. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
4. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
7. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
8. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
9. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
10. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
11. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
Post Your Comments:
(Date:1/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ... stock of Solta Medical, Inc. (NASDAQ: SLTM ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
(Date:1/14/2014)... HILLSBORO, Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- ... and a targeting guide with accompanying instrumentation to place ... new adjunct to the soft tissue (e.g. ligament) repair ... soft tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... WASHINGTON, Dec. 6, 2011  BodyMedia, the leading developer ... Qualcomm Life, a wholly owned subsidiary of Qualcomm ... BodyMedia FIT ™ LINK Armband ... BodyMedia Armband users to share wireless health data, ...
... 6, 2011  Echo Therapeutics, Inc. (Nasdaq: ECTE ... a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system ... today announced a registered direct equity financing of approximately ... of one share of its common stock and a ...
Cached Medicine Technology:BodyMedia Plans to Join Qualcomm Life's Wireless Health 2net Ecosystem 2BodyMedia Plans to Join Qualcomm Life's Wireless Health 2net Ecosystem 3BodyMedia Plans to Join Qualcomm Life's Wireless Health 2net Ecosystem 4Echo Therapeutics Announces Pricing of $5.4 Million Registered Direct Equity Financing 2Echo Therapeutics Announces Pricing of $5.4 Million Registered Direct Equity Financing 3
(Date:7/9/2014)... may smell of flatulence and have a reputation for being ... hydrogen sulfide is now being being found to offer potential ... stroke, heart attacks and dementia. A new compound (AP39), designed ... key to future therapies, by targeting delivery of very small ... inside cells. , Scientists in Exeter have already found ...
(Date:7/9/2014)... most important organs in the human body. Its job ... this is its synthesis function and that ... is its detoxification function. Lack of exercise and too ... liver. The resulting diseased cells can lead to inflammations, ... According to the German Liver Foundation, over five million ...
(Date:7/9/2014)... printing on prescription labels handed out by pharmacists ... in taking medication, according to new research by ... Institute for the Blind)., The study, published recently ... that labels on prescription medications dispensed by pharmacies ... legibility. , By simply following recommended guidelines for ...
(Date:7/9/2014)... , , , , ... , , , , ... rifle and the microphone is 50m downrange from the firer and approximately 30cm from the bullet... , ... , , , , , , ... , , , , , , , ...
(Date:7/9/2014)... diseases has risen dramatically in Western societies. One frequently ... microorganisms and have fewer infections than previous generations, thereby ... by researchers at Sahlgrenska Academy, University of Gothenburg, monitored ... of the immune system in relation to allergic disease. ... the Vstra Gtaland Region, half of them on farms ...
Breaking Medicine News(10 mins):Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7
... SATURDAY, Oct. 1 (HealthDay News) -- Halloween candy may ... unexpected allergy and asthma triggers that can pose a ... makeup, according to experts from the American College of ... of Halloween-associated allergies, they focus on candy and often ...
... 30, 2011Young adults undergoing addiction treatment arrive ready and ... recovery, but it,s the help and guidance received during ... a longitudinal study published electronically and in press within ... study was conducted collaboratively by the Center for Addiction ...
... late nineties, researchers from a promising yet volatile French ... their own horse. The seven founders teamed-up with ... industry and with Gemmes Ventures, an investment fund specialising ... names such as Rotschild are backing CrossJect, which is ...
... Ph.D., vice president of research for Lifespan ( www.lifespan.org ), ... the annual ceremony last night at Harvard University. Snyder, along ... and Yale Medical School, were recognized for their work which ... have the same impact on impairing cognitive function as small ...
... A program designed to accelerate the entry of ... following completion of their graduate research degree or ... National Institutes of Health Director,s Early Independence Awards ... empower the biomedical research workforce, particularly through the ...
... Men over 75 with prostate cancer who are otherwise healthy ... study. Meanwhile, younger men with prostate cancer who ... -- are being treated for their cancer, but not responding ... researchers found. "This study suggests that men with certain ...
Cached Medicine News:Health News:Halloween Trappings Can Trigger Asthma, Allergies 2Health News:Study shows young adults want to recover from addiction but need help to make it happen 2Health News:An innovation star for Europe 2Health News:An innovation star for Europe 3Health News:Lifespan researcher wins Ig Nobel Prize 2Health News:NIH program allows junior investigators to bypass traditional post-doc training 2Health News:Otherwise Healthy Older Men Undertreated for Prostate Cancer: Study 2Health News:Otherwise Healthy Older Men Undertreated for Prostate Cancer: Study 3
125I radioimmunoassay, Simple extraction procedure, Ready-to-use calibrators, Less than 0.1% crossreactivity with DHEA-SO4, 2-hour single incubation, 37C, Calibration Range: 0.5 30 ng/mL...
Inquire...
EL-RF/3 is for measurement of IgM, IgG, IgA RF with high specificity for rheumatoid arthritis....
Rapid latex slide agglutination assay for the qualitative and semi-quantitative determination of Rheumatoid Factors in human serum....
Medicine Products: